ClinicalTrials.gg
CompletedNCT03175120DUAL™ II ChinaUpdated Mar 19, 2020Results posted

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

A Phase 3 interventional study of Insulin degludec/liraglutide and Insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-19.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
25th of 70
453 · median 384
Started
2017
with 4 others
Phase 3
49 of 70
2 open now
Registered
53rd of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 25th largest by enrollment, is one of 5 that started in 2017, is one of 49 in phase 3, and was the 53rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 453 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including procedures to determine suitability for the trial - Male or female, age at least 18 years at the time of signing inform consent - Type 2 diabetes mellitus (clinically diagnosed) - (glycosylated ) above or equal to 7.5% by central laboratory analysis, with the aim of a median of 8.5%. When approximately 50% of the randomised subjects have an HbA1c above 8.5%, the remaining subjects randomised must have an HbA1c below or equal to 8.5% or when approximately 50% of the subjects randomised have an HbA1c below or equal to 8.5%, the remaining subjects randomised must have an HbA1c above 8.5% - Current treatment for at least 90 calendar days prior to screening with basal insulin plus metformin plus/minus α-glucosidase inhibitors, sulphonylureas, glinides or thiazolidinediones. Subjects should be on a stable dose for at least 60 calendar days prior to screening of: Basal insulin 20-50 units (U)/day (both inclusive) ( Individual fluctuations of plus/minus 5U during the 60 day period prior to the day of screening are acceptable.) on the day of screening in combination with: - Metformin (above or equal to 1500 mg or max tolerated dose) or - Metformin (above or equal to 1500 mg or max tolerated dose) and sulphonylureas (above or equal to half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and glinide (at least half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and α-glucosidase inhibitors (AGI) (at least half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and thiazolidinediones (at least half of the max approved dose according to local label) - (BMI) above or equal to 24 kg/m\^2 Exclusion Criteria: Current use of any antidiabetic drug (except for basal insulin, metformin, α-glucosidase inhibitors, sulphonylureas, glinides or thiazolidinediones) or anticipated change in concomitant medication, that in the investigator´s opinion could interfere with glucose level (e.g. systemic ) - Treatment with glucagon like peptide -1 receptor agonists, or dipeptidyl-peptidase-4 inhibitors or insulin (except for basal insulin) within 90 days prior to Visit 1 - Impaired liver function defined as above or equal to 2.5 times upper normal range - Impaired renal function defined as serum-creatinine above or equal to 133 μmol/L for males and above or equal to 125 μmol/L for females, or as defined according to local for metformin Screening calcitonin above or equal to 50 ng/L - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) - Cardiac disorder defined as: congestive heart failure ( class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 12 months prior to screening and/or planned coronary, carotid or peripheral artery revascularisation procedures - Severe uncontrolled treated or untreated hypertension (systolic blood pressure above or equal to 180 mm Hg or diastolic blood pressure above or equal to 100 mm Hg) - Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment - History of pancreatitis (acute or chronic)

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    Insulin degludec/liraglutide

    Drug: Insulin degludec/liraglutide

  • Active comparator
    Insulin degludec

    Drug: Insulin degludec

Interventions

  • DrugInsulin degludec/liraglutide

    Drug pages: Insulin degludec · Liraglutide

    Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

  • Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

07

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change in Body Weight

    Change in body weight from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  2. Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes

    Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed hypoglycaemic episodes during 26 weeks of treatment is presented.

    Time frame: Up to 26 weeks

  3. Change in Fasting Plasma Glucose (FPG)

    Change in FPG from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  4. Change in Waist Circumference

    Change in waist circumference from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  5. Change in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile

    Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  6. Change in SMPG-mean Post Prandial Increments

    Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  7. Insulin Dose

    The mean of actual daily total insulin dose after 26 weeks of treatment is presented.

    Time frame: Week 26

  8. SMPG-9-point Profile (Individual Points in the Profile)

    Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. SMPG-9-point profile (individual points in the profile) at week 26 is presented.

    Time frame: Week 26

  9. Change in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline

    Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  10. Change in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline

    Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  11. Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline

    Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  12. Change in Fasting Total Cholesterol- Ratio to Baseline

    Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  13. Change in Fasting Triglycerides- Ratio to Baseline

    Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  14. Change in Fasting Free Fatty Acids- Ratio to Baseline

    Change in fasting free fatty acids (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  15. Change in Fasting C-peptide- Ratio to Baseline

    Change in fasting C-peptide (measured in nanomoles per liter (nmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  16. Change in Fasting Insulin- Ratio to Baseline

    Change in fasting insulin (measured in picomoles per liter (pmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  17. Change in Fasting Glucagon- Ratio to Baseline

    Change in fasting glucagon (measured in picograms per milliliter (pg/mL)) from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  18. Change in HOMA-B (Beta-cell Function)- Ratio to Baseline

    Change in HOMA-B from baseline (week 0) to week 26 is presented as ratio to baseline.

    Time frame: Week 0, week 26

  19. Participants Who Achieved HbA1c < 7.0%, ADA Target (Yes/no)

    Participants who achieved HbA1c \< 7.0%, ADA target (yes/no) is presented.

    Time frame: Week 26

  20. Participants Who Achieved HbA1c ≤ 6.5%, American Association of Clinical Endocrinologists (AACE) Target (Yes/no)

    Participants who achieved HbA1c ≤ 6.5%, AACE target (yes/no) is presented.

    Time frame: Week 26

  21. Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero

    Participants who achieved HbA1c \< 7.0% and change from baseline in body weight below or equal to zero is presented.

    Time frame: Week 26

  22. Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero

    Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero is presented.

    Time frame: Week 26

  23. Participants Who Achieved HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes

    Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \< 7.0% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.

    Time frame: Week 26

  24. Participants Who Achieved HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes

    Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.

    Time frame: Week 26

  25. Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes

    Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \< 7.0% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.

    Time frame: Week 26

  26. Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes

    Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.

    Time frame: Week 26

  27. Number of Treatment-emergent Adverse Events (TEAEs)

    A TEAE was defined as an adverse event with onset date on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.

    Time frame: Weeks 0-27

  28. Number of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes

    Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed hypoglycaemic episodes is presented.

    Time frame: Weeks 0-27

  29. Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes is presented.

    Time frame: Weeks 0-27

  30. Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes is presented.

    Time frame: Weeks 0-27

  31. Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition

    Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA definition is presented.

    Time frame: Weeks 0-27

  32. Change in Physical Examination

    Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at week -2 and week 26 is presented.

    Time frame: Week -2, week 26

  33. Eye Examination

    Dilated fundoscopy or fundus photography was performed by the investigator at week -2 and week 26. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week -2 and week 26 were presented.

    Time frame: Week -2, week 26

  34. Change in Electrocardiogram (ECG)

    The ECG was assessed by the investigator at baseline (week -2) and week 26 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 26 were presented.

    Time frame: Week -2, week 26

  35. Change in Pulse

    Change in pulse from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  36. Change in Blood Pressure (Systolic and Diastolic Blood Pressure)

    Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  37. Change in Biochemical Parameter- Amylase, Lipase, Creatinine Kinase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)

    Change in amylase, lipase, creatinine kinase, ALT, AST, ALP from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  38. Change in Biochemical Parameter-calcium (Total), Albumin Corrected Calcium, Potassium, Sodium, Urea

    Change in calcium (total), albumin corrected calcium, potassium, sodium, urea from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  39. Change in Albumin

    Change in albumin from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  40. Change in Total Bilirubin

    Change in total bilirubin from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  41. Change in Creatinine

    Change in creatinine from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  42. Change in Total Protein

    Change in total protein from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  43. Change in Haematological Parameter- Haematocrit

    Change in haematocrit from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  44. Change in Haematological Parameter- Haemoglobin

    Change in haemoglobin from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  45. Change in Haematological Parameter- Leukocytes and Thrombocytes

    Change in leukocytes and thrombocytes from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  46. Change in Haematological Parameter- Erythrocytes

    Change in erythrocytes from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  47. Change in Haematological Parameter- Basophils

    Change in basophils from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  48. Change in Haematological Parameter- Eosinophils

    Change in eosinophils from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  49. Change in Haematological Parameter- Lymphocytes

    Change in lymphocytes from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  50. Change in Haematological Parameter- Monocytes

    Change in monocytes from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  51. Change in Haematological Parameter- Neutrophils

    Change in neutrophils from baseline (week 0) to week 26 is presented.

    Time frame: Week 0, week 26

  52. Change in Calcitonin

    Calcitonin levels were measured and were categorised as low, normal or high. Number of participants in each category at week 0 and week 26 were presented.

    Time frame: Week 0, week 26

  53. Urinalysis (Erythrocytes, Protein, Glucose and Ketones)

    The urinalysis was the measurements of protein, glucose, erythrocytes and ketones at week 0 and week 26 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at week 0 and week 26 are presented.

    Time frame: Week 0, week 26

  54. Anti-insulin Degludec Specific Antibodies

    Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).

    Time frame: Week 27

  55. Antibodies Cross-reacting to Human Insulin

    Serum samples were analysed for the presence of antibodies cross-reacting to human insulin. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).

    Time frame: Week 27

  56. Total Insulin Antibodies

    Serum samples were analysed for the presence of total insulin antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).

    Time frame: Week 27

  57. Occurrence of Anti-liraglutide Antibodies (Yes/no)

    This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies at week 27 are presented.

    Time frame: Week 27

  58. Occurrence of Anti-liraglutide Antibodies Cross Reacting Native Glucagon-like Peptide-1 (GLP-1)

    This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.

    Time frame: Week 27

  59. Occurrence of Neutralising Liraglutide Antibodies

    This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.

    Time frame: Week 27

  60. Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1

    This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.

    Time frame: Week 27

08

Results

Posted Mar 19, 2020

Participant flow

The trial was conducted at 40 sites in China.

Participant flow — Overall Study
MilestoneInsulin Degludec/LiraglutideInsulin Degludec
Started302151
Treated301151
Full analysis set (fas)302151
Safety analysis set (sas)301151
Completed290139
Not completed1212
Withdrew: Adverse event22
Withdrew: Protocol violation52
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject25
Withdrew: Other23

Outcome measures

PrimaryChange in HbA1c

Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage point of HbA1c
Change in HbA1c
Percentage point of HbA1cInsulin Degludec/LiraglutideInsulin Degludec
Change in HbA1c-1.93 ± 1.14-1.06 ± 1.19
Statistical analysis
  • Insulin Degludec/Liraglutide vs Insulin Degludec · ANCOVA · p = <.0001 · Treatment contrast: -0.92 · 95% CI -1.09 to -0.75
SecondaryChange in Body Weight

Change in body weight from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Kilogram (kg)
Change in Body Weight
Kilogram (kg)Insulin Degludec/LiraglutideInsulin Degludec
Change in Body Weight-0.7 ± 3.00.5 ± 2.7
SecondaryNumber of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes

Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed hypoglycaemic episodes during 26 weeks of treatment is presented.

Time frame:
Up to 26 weeks
Reported as:
Number · Episodes
Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
EpisodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes3836
SecondaryChange in Fasting Plasma Glucose (FPG)

Change in FPG from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Plasma Glucose (FPG)-3.57 ± 3.00-2.82 ± 3.15
SecondaryChange in Waist Circumference

Change in waist circumference from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Centimeter (cm)
Change in Waist Circumference
Centimeter (cm)Insulin Degludec/LiraglutideInsulin Degludec
Change in Waist Circumference-0.4 ± 4.30.7 ± 3.3
SecondaryChange in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile

Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Change in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile-3.35 ± 2.63-2.31 ± 2.61
SecondaryChange in SMPG-mean Post Prandial Increments

Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in SMPG-mean Post Prandial Increments
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Change in SMPG-mean Post Prandial Increments0.08 ± 2.190.28 ± 2.71
SecondaryInsulin Dose

The mean of actual daily total insulin dose after 26 weeks of treatment is presented.

Time frame:
Week 26
Reported as:
Mean · Units of insulin (U)
Insulin Dose
Units of insulin (U)Insulin Degludec/LiraglutideInsulin Degludec
Insulin Dose34.6 ± 11.137.9 ± 10.8
SecondarySMPG-9-point Profile (Individual Points in the Profile)

Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. SMPG-9-point profile (individual points in the profile) at week 26 is presented.

Time frame:
Week 26
Reported as:
Mean · mmol/L
SMPG-9-point Profile (Individual Points in the Profile)
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Before breakfast5.48 ± 1.065.88 ± 1.30
90 minutes after start of breakfast9.51 ± 2.6610.50 ± 2.45
Before lunch6.93 ± 2.108.17 ± 3.19
90 minutes after start of lunch9.68 ± 2.5211.21 ± 2.93
Before main evening meal7.24 ± 2.167.87 ± 2.65
90 minutes after main evening meal9.87 ± 2.5310.86 ± 2.46
At bedtime8.57 ± 2.529.52 ± 2.61
At 4:00 a.m.5.97 ± 1.496.61 ± 1.99
Before breakfast the following day5.48 ± 1.145.83 ± 1.52
SecondaryChange in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline

Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of HDL cholesterol
Change in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline
Ratio of HDL cholesterolInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline1.00 ± 17.51.03 ± 15.9
SecondaryChange in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline

Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of LDL cholesterol
Change in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline
Ratio of LDL cholesterolInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline0.89 ± 32.50.95 ± 37.7
SecondaryChange in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline

Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of VLDL cholesterol
Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline
Ratio of VLDL cholesterolInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline0.92 ± 55.20.93 ± 49.1
SecondaryChange in Fasting Total Cholesterol- Ratio to Baseline

Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Fasting Total Cholesterol- Ratio to Baseline
Ratio of total cholesterolInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Total Cholesterol- Ratio to Baseline0.92 ± 19.10.97 ± 20.0
SecondaryChange in Fasting Triglycerides- Ratio to Baseline

Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of triglycerides
Change in Fasting Triglycerides- Ratio to Baseline
Ratio of triglyceridesInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Triglycerides- Ratio to Baseline0.91 ± 63.70.92 ± 55.8
SecondaryChange in Fasting Free Fatty Acids- Ratio to Baseline

Change in fasting free fatty acids (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of free fatty acids
Change in Fasting Free Fatty Acids- Ratio to Baseline
Ratio of free fatty acidsInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Free Fatty Acids- Ratio to Baseline0.65 ± 76.40.64 ± 61.9
SecondaryChange in Fasting C-peptide- Ratio to Baseline

Change in fasting C-peptide (measured in nanomoles per liter (nmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of C-peptide
Change in Fasting C-peptide- Ratio to Baseline
Ratio of C-peptideInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting C-peptide- Ratio to Baseline0.64 ± 71.20.52 ± 71.8
SecondaryChange in Fasting Insulin- Ratio to Baseline

Change in fasting insulin (measured in picomoles per liter (pmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of insulin
Change in Fasting Insulin- Ratio to Baseline
Ratio of insulinInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Insulin- Ratio to Baseline0.63 ± 118.30.50 ± 106.4
SecondaryChange in Fasting Glucagon- Ratio to Baseline

Change in fasting glucagon (measured in picograms per milliliter (pg/mL)) from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of glucagon
Change in Fasting Glucagon- Ratio to Baseline
Ratio of glucagonInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Glucagon- Ratio to Baseline1.01 ± 95.81.09 ± 81.7
SecondaryChange in HOMA-B (Beta-cell Function)- Ratio to Baseline

Change in HOMA-B from baseline (week 0) to week 26 is presented as ratio to baseline.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio of beta-cell function
Change in HOMA-B (Beta-cell Function)- Ratio to Baseline
Ratio of beta-cell functionInsulin Degludec/LiraglutideInsulin Degludec
Change in HOMA-B (Beta-cell Function)- Ratio to Baseline1.47 ± 115.00.99 ± 113.4
SecondaryParticipants Who Achieved HbA1c < 7.0%, ADA Target (Yes/no)

Participants who achieved HbA1c \< 7.0%, ADA target (yes/no) is presented.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Participants Who Achieved HbA1c < 7.0%, ADA Target (Yes/no)
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes15123
No138115
SecondaryParticipants Who Achieved HbA1c ≤ 6.5%, American Association of Clinical Endocrinologists (AACE) Target (Yes/no)

Participants who achieved HbA1c ≤ 6.5%, AACE target (yes/no) is presented.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Participants Who Achieved HbA1c ≤ 6.5%, American Association of Clinical Endocrinologists (AACE) Target (Yes/no)
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes9610
No193128
SecondaryParticipants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero

Participants who achieved HbA1c \< 7.0% and change from baseline in body weight below or equal to zero is presented.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes987
No204144
SecondaryParticipants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero

Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero is presented.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes593
No243148
SecondaryParticipants Who Achieved HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes

Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \< 7.0% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Participants Who Achieved HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes14822
No154129
SecondaryParticipants Who Achieved HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes

Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Participants Who Achieved HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes939
No209142
SecondaryParticipants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes

Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \< 7.0% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes947
No208144
SecondaryParticipants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes

Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes583
No244148
SecondaryNumber of Treatment-emergent Adverse Events (TEAEs)

A TEAE was defined as an adverse event with onset date on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.

Time frame:
Weeks 0-27
Reported as:
Number · Adverse events
Number of Treatment-emergent Adverse Events (TEAEs)
Adverse eventsInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment-emergent Adverse Events (TEAEs)641230
SecondaryNumber of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes

Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed hypoglycaemic episodes is presented.

Time frame:
Weeks 0-27
Reported as:
Number · Episodes
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes
EpisodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes98
SecondaryNumber of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes is presented.

Time frame:
Weeks 0-27
Reported as:
Number · Episodes
Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes2321
SecondaryNumber of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes is presented.

Time frame:
Weeks 0-27
Reported as:
Number · Episodes
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
EpisodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes77
SecondaryNumber of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition

Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA definition is presented.

Time frame:
Weeks 0-27
Reported as:
Number · Episodes
Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition
EpisodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition1099680
SecondaryChange in Physical Examination

Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at week -2 and week 26 is presented.

Time frame:
Week -2, week 26
Reported as:
Count of participants · Participants
Change in Physical Examination
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Week-2: Cardiovascular system — Normal299149
Week-2: Cardiovascular system — Abnormal NCS10
Week-2: Cardiovascular system — Abnormal CS12
Week 26: Cardiovascular system — Normal286137
Week 26: Cardiovascular system — Abnormal NCS10
Week 26: Cardiovascular system — Abnormal CS12
Week-2: Central and peripheral nervous system — Normal299150
Week-2: Central and peripheral nervous system — Abnormal NCS20
Week-2: Central and peripheral nervous system — Abnormal CS01
Week 26: Central and peripheral nervous system — Normal287139
Week 26: Central and peripheral nervous system — Abnormal NCS10
Week 26: Central and peripheral nervous system — Abnormal CS00
Week -2: Gastrointestinal system — Normal299150
Week -2: Gastrointestinal system — Abnormal NCS21
Week -2: Gastrointestinal system — Abnormal CS00
Week 26: Gastrointestinal system — Normal285139
Week 26: Gastrointestinal system — Abnormal NCS20
Week 26: Gastrointestinal system — Abnormal CS10
Week -2: General appearance — Normal283141
Week -2: General appearance — Abnormal NCS112
Week -2: General appearance — Abnormal CS78
Week 26: General appearance — Normal273130
Week 26: General appearance — Abnormal NCS92
Week 26: General appearance — Abnormal CS67
Week -2: Head, eyes, ENTand Neck — Normal295147
Week -2: Head, eyes, ENTand Neck — Abnormal NCS22
Week -2: Head, eyes, ENTand Neck — Abnormal CS42
Week 26: Head, eyes, ENTand Neck — Normal283137
Week 26: Head, eyes, ENTand Neck — Abnormal NCS21
Week 26: Head, eyes, ENTand Neck — Abnormal CS31
Week -2: Lymph node palpation — Normal301151
Week -2: Lymph node palpation — Abnormal NCS00
Week -2: Lymph node palpation — Abnormal CS00
Week 26: Lymph node palpation — Normal288139
Week 26: Lymph node palpation — Abnormal NCS00
Week 26: Lymph node palpation — Abnormal CS00
Week -2: Musculoskeletal system — Normal296145
Week -2: Musculoskeletal system — Abnormal NCS23
Week -2: Musculoskeletal system — Abnormal CS33
Week 26: Musculoskeletal system — Normal280137
Week 26: Musculoskeletal system — Abnormal NCS31
Week 26: Musculoskeletal system — Abnormal CS51
Week -2: Respiratory system — Normal301151
Week -2: Respiratory system — Abnormal NCS00
Week -2: Respiratory system — Abnormal CS00
Week 26: Respiratory system — Normal288139
Week 26: Respiratory system — Abnormal NCS00
Week 26: Respiratory system — Abnormal CS00
Week -2: Skin — Normal270132
Week -2: Skin — Abnormal NCS2213
Week -2: Skin — Abnormal CS96
Week 26: Skin — Normal259126
Week 26: Skin — Abnormal NCS229
Week 26: Skin — Abnormal CS74
Week -2: Thyroid gland — Normal295147
Week -2: Thyroid gland — Abnormal NCS42
Week -2: Thyroid gland — Abnormal CS22
Week 26: Thyroid gland — Normal284134
Week 26: Thyroid gland — Abnormal NCS33
Week 26: Thyroid gland — Abnormal CS12
SecondaryEye Examination

Dilated fundoscopy or fundus photography was performed by the investigator at week -2 and week 26. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week -2 and week 26 were presented.

Time frame:
Week -2, week 26
Reported as:
Count of participants · Participants
Eye Examination
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Week -2: Left eye — Normal16787
Week -2: Left eye — Abnormal NCS3415
Week -2: Left eye — Abnormal CS10049
Week 26: Left eye — Normal14780
Week 26: Left eye — Abnormal NCS3514
Week 26: Left eye — Abnormal CS10545
Week -2: Right eye — Normal16285
Week -2: Right eye — Abnormal NCS4118
Week -2: Right eye — Abnormal CS9847
Week 26: Right eye — Normal13984
Week 26: Right eye — Abnormal NCS3712
Week 26: Right eye — Abnormal CS11142
SecondaryChange in Electrocardiogram (ECG)

The ECG was assessed by the investigator at baseline (week -2) and week 26 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 26 were presented.

Time frame:
Week -2, week 26
Reported as:
Count of participants · Participants
Change in Electrocardiogram (ECG)
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Week -2 — Normal17590
Week -2 — Abnormal NCS7641
Week -2 — Abnormal CS5020
Week 26 — Normal17591
Week 26 — Abnormal NCS7332
Week 26 — Abnormal CS3916
SecondaryChange in Pulse

Change in pulse from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Beats per minute (beats/min)
Change in Pulse
Beats per minute (beats/min)Insulin Degludec/LiraglutideInsulin Degludec
Change in Pulse5.7 ± 9.61.3 ± 8.7
SecondaryChange in Blood Pressure (Systolic and Diastolic Blood Pressure)

Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Millimeters of mercury (mmHg)Insulin Degludec/LiraglutideInsulin Degludec
Systolic blood pressure-3.5 ± 13.6-0.5 ± 12.5
Diastolic blood pressure0.1 ± 7.8-0.4 ± 8.1
SecondaryChange in Biochemical Parameter- Amylase, Lipase, Creatinine Kinase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)

Change in amylase, lipase, creatinine kinase, ALT, AST, ALP from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Units per liter (U/L)
Change in Biochemical Parameter- Amylase, Lipase, Creatinine Kinase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)
Units per liter (U/L)Insulin Degludec/LiraglutideInsulin Degludec
Amylase10.45 ± 23.142.69 ± 11.72
Lipase16.97 ± 35.24-0.35 ± 13.81
Creatinine kinase3.32 ± 65.176.99 ± 84.31
ALT-3.02 ± 12.03-4.06 ± 11.97
AST-1.42 ± 7.46-2.06 ± 7.92
ALP-1.62 ± 13.30-1.70 ± 11.39
SecondaryChange in Biochemical Parameter-calcium (Total), Albumin Corrected Calcium, Potassium, Sodium, Urea

Change in calcium (total), albumin corrected calcium, potassium, sodium, urea from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Biochemical Parameter-calcium (Total), Albumin Corrected Calcium, Potassium, Sodium, Urea
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Calcium (total)0.01 ± 0.10-0.01 ± 0.09
Albumin corrected calcium-0.00 ± 0.08-0.01 ± 0.08
Potassium-0.03 ± 0.34-0.11 ± 0.35
Sodium1.03 ± 2.471.40 ± 2.43
Urea-0.09 ± 1.320.17 ± 1.29
SecondaryChange in Albumin

Change in albumin from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Grams per deciliter (g/dL)
Change in Albumin
Grams per deciliter (g/dL)Insulin Degludec/LiraglutideInsulin Degludec
Change in Albumin0.05 ± 0.290.02 ± 0.25
SecondaryChange in Total Bilirubin

Change in total bilirubin from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Micromoles per liter (umol/L)
Change in Total Bilirubin
Micromoles per liter (umol/L)Insulin Degludec/LiraglutideInsulin Degludec
Change in Total Bilirubin-0.30 ± 3.89-0.54 ± 3.66
SecondaryChange in Creatinine

Change in creatinine from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · umol/L
Change in Creatinine
umol/LInsulin Degludec/LiraglutideInsulin Degludec
Change in Creatinine0.44 ± 7.93-0.32 ± 7.52
SecondaryChange in Total Protein

Change in total protein from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · g/dL
Change in Total Protein
g/dLInsulin Degludec/LiraglutideInsulin Degludec
Change in Total Protein0.08 ± 0.410.03 ± 0.39
SecondaryChange in Haematological Parameter- Haematocrit

Change in haematocrit from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage of red blood cells
Change in Haematological Parameter- Haematocrit
Percentage of red blood cellsInsulin Degludec/LiraglutideInsulin Degludec
Change in Haematological Parameter- Haematocrit-0.07 ± 2.56-0.12 ± 2.14
SecondaryChange in Haematological Parameter- Haemoglobin

Change in haemoglobin from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Haematological Parameter- Haemoglobin
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Change in Haematological Parameter- Haemoglobin-0.08 ± 0.52-0.09 ± 0.41
SecondaryChange in Haematological Parameter- Leukocytes and Thrombocytes

Change in leukocytes and thrombocytes from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · 10^9 cells per liter (10^9/L)
Change in Haematological Parameter- Leukocytes and Thrombocytes
10^9 cells per liter (10^9/L)Insulin Degludec/LiraglutideInsulin Degludec
Leukocytes0.32 ± 1.390.31 ± 1.18
Thrombocytes14.13 ± 34.3412.19 ± 34.01
SecondaryChange in Haematological Parameter- Erythrocytes

Change in erythrocytes from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · 10^12 cells per liter (10^12/L)
Change in Haematological Parameter- Erythrocytes
10^12 cells per liter (10^12/L)Insulin Degludec/LiraglutideInsulin Degludec
Change in Haematological Parameter- Erythrocytes-0.06 ± 0.26-0.05 ± 0.24
SecondaryChange in Haematological Parameter- Basophils

Change in basophils from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage of basophils
Change in Haematological Parameter- Basophils
Percentage of basophilsInsulin Degludec/LiraglutideInsulin Degludec
Change in Haematological Parameter- Basophils0.00 ± 0.340.01 ± 0.27
SecondaryChange in Haematological Parameter- Eosinophils

Change in eosinophils from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage of eosinophils
Change in Haematological Parameter- Eosinophils
Percentage of eosinophilsInsulin Degludec/LiraglutideInsulin Degludec
Change in Haematological Parameter- Eosinophils-0.15 ± 1.84-0.25 ± 1.72
SecondaryChange in Haematological Parameter- Lymphocytes

Change in lymphocytes from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage of lymphocytes
Change in Haematological Parameter- Lymphocytes
Percentage of lymphocytesInsulin Degludec/LiraglutideInsulin Degludec
Change in Haematological Parameter- Lymphocytes-1.00 ± 6.95-0.82 ± 6.41
SecondaryChange in Haematological Parameter- Monocytes

Change in monocytes from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage of monocytes
Change in Haematological Parameter- Monocytes
Percentage of monocytesInsulin Degludec/LiraglutideInsulin Degludec
Change in Haematological Parameter- Monocytes-0.19 ± 2.02-0.06 ± 2.19
SecondaryChange in Haematological Parameter- Neutrophils

Change in neutrophils from baseline (week 0) to week 26 is presented.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage of neutrophils
Change in Haematological Parameter- Neutrophils
Percentage of neutrophilsInsulin Degludec/LiraglutideInsulin Degludec
Change in Haematological Parameter- Neutrophils1.34 ± 7.850.99 ± 7.41
SecondaryChange in Calcitonin

Calcitonin levels were measured and were categorised as low, normal or high. Number of participants in each category at week 0 and week 26 were presented.

Time frame:
Week 0, week 26
Reported as:
Count of participants · Participants
Change in Calcitonin
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Week 0 — Low00
Week 0 — Normal293149
Week 0 — High82
Week 26 — Low00
Week 26 — Normal279136
Week 26 — High103
SecondaryUrinalysis (Erythrocytes, Protein, Glucose and Ketones)

The urinalysis was the measurements of protein, glucose, erythrocytes and ketones at week 0 and week 26 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at week 0 and week 26 are presented.

Time frame:
Week 0, week 26
Reported as:
Count of participants · Participants
Urinalysis (Erythrocytes, Protein, Glucose and Ketones)
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Week 0: Erythrocytes — Negative258121
Week 0: Erythrocytes — Trace3322
Week 0: Erythrocytes — 1+34
Week 0: Erythrocytes — 2+23
Week 0: Erythrocytes — 3+41
Week 26: Erythrocytes — Negative255120
Week 26: Erythrocytes — Trace2211
Week 26: Erythrocytes — 1+61
Week 26: Erythrocytes — 2+24
Week 26: Erythrocytes — 3+23
Week 0: Glucose — Negative17192
Week 0: Glucose — Trace3313
Week 0: Glucose — 1+3017
Week 0: Glucose — 2+2513
Week 0: Glucose — 3+4116
Week 26: Glucose — Negative256110
Week 26: Glucose — Trace1416
Week 26: Glucose — 1+109
Week 26: Glucose — 2+42
Week 26: Glucose — 3+32
Week 0: Ketones — Negative274137
Week 0: Ketones — Trace2110
Week 0: Ketones — 1+54
Week 0: Ketones — 2+00
Week 0: Ketones — 3+00
Week 26: Ketones — Negative272132
Week 26: Ketones — Trace147
Week 26: Ketones — 1+10
Week 26: Ketones — 2+00
Week 26: Ketones — 3+00
Week 0: Protein — Negative17289
Week 0: Protein — Trace7232
Week 0: Protein — 1+3618
Week 0: Protein — 2+1610
Week 0: Protein — 3+42
Week 26: Protein — Negative19889
Week 26: Protein — Trace4722
Week 26: Protein — 1+2918
Week 26: Protein — 2+119
Week 26: Protein — 3+21
SecondaryAnti-insulin Degludec Specific Antibodies

Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).

Time frame:
Week 27
Reported as:
Mean · %B/T
Anti-insulin Degludec Specific Antibodies
%B/TInsulin Degludec/LiraglutideInsulin Degludec
Anti-insulin Degludec Specific Antibodies0.25 ± 1.250.13 ± 0.57
SecondaryAntibodies Cross-reacting to Human Insulin

Serum samples were analysed for the presence of antibodies cross-reacting to human insulin. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).

Time frame:
Week 27
Reported as:
Mean · %B/T
Antibodies Cross-reacting to Human Insulin
%B/TInsulin Degludec/LiraglutideInsulin Degludec
Antibodies Cross-reacting to Human Insulin9.07 ± 16.618.64 ± 16.84
SecondaryTotal Insulin Antibodies

Serum samples were analysed for the presence of total insulin antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).

Time frame:
Week 27
Reported as:
Mean · %B/T
Total Insulin Antibodies
%B/TInsulin Degludec/LiraglutideInsulin Degludec
Total Insulin Antibodies9.31 ± 17.338.77 ± 17.19
SecondaryOccurrence of Anti-liraglutide Antibodies (Yes/no)

This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies at week 27 are presented.

Time frame:
Week 27
Reported as:
Count of participants · Participants
Occurrence of Anti-liraglutide Antibodies (Yes/no)
ParticipantsInsulin Degludec/Liraglutide
Yes24
No264
SecondaryOccurrence of Anti-liraglutide Antibodies Cross Reacting Native Glucagon-like Peptide-1 (GLP-1)

This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.

Time frame:
Week 27
Reported as:
Count of participants · Participants
Occurrence of Anti-liraglutide Antibodies Cross Reacting Native Glucagon-like Peptide-1 (GLP-1)
ParticipantsInsulin Degludec/Liraglutide
Yes6
SecondaryOccurrence of Neutralising Liraglutide Antibodies

This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.

Time frame:
Week 27
Reported as:
Count of participants · Participants
Occurrence of Neutralising Liraglutide Antibodies
ParticipantsInsulin Degludec/Liraglutide
Yes0
SecondaryOccurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1

This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.

Time frame:
Week 27
Reported as:
Count of participants · Participants
Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1
ParticipantsInsulin Degludec/Liraglutide
Yes0

Adverse events

Collected over Weeks 0-30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec/Liraglutide0/301 (0%)13/301 (4.3%)113/301 (37.5%)
Insulin Degludec0/151 (0%)7/151 (4.6%)43/151 (28.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventInsulin Degludec/LiraglutideInsulin Degludec
Coronary artery diseaseCardiac disorders0/3012/151
Angina unstableCardiac disorders1/3011/151
Cerebral infarctionNervous system disorders0/3011/151
Coronary artery stenosisCardiac disorders0/3011/151
EpiglottitisInfections and infestations0/3011/151
Femur fractureInjury, poisoning and procedural complications0/3011/151
CataractEye disorders1/3010/151
ConstipationGastrointestinal disorders1/3010/151
DiarrhoeaGastrointestinal disorders1/3010/151
Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3010/151
Most frequent other events
Most frequent other events
EventInsulin Degludec/LiraglutideInsulin Degludec
Upper respiratory tract infectionInfections and infestations38/30127/151
Lipase increasedInvestigations36/3013/151
Diabetic retinopathyEye disorders35/30111/151
DiarrhoeaGastrointestinal disorders22/3012/151
Decreased appetiteMetabolism and nutrition disorders21/3013/151

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)Insulin Degludec/LiraglutideInsulin DegludecTotal
Mean54.5 ± 9.855.3 ± 10.054.7 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/LiraglutideInsulin DegludecTotal
Female11960179
Male18391274
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin Degludec/LiraglutideInsulin DegludecTotal
Hispanic or Latino000
Not Hispanic or Latino302151453
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Degludec/LiraglutideInsulin DegludecTotal
American Indian or Alaska Native000
Asian302151453
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(Percentage of HbA1c)Insulin Degludec/LiraglutideInsulin DegludecTotal
Mean8.93 ± 1.208.96 ± 1.178.94 ± 1.19
09

Study locations

37 sites
  • Novo Nordisk Investigational Site
    Hefei, Anhui 230001, China
  • Novo Nordisk Investigational Site
    Hefei, Anhui 230061, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100071, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100088, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100730, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100853, China
  • Novo Nordisk Investigational Site
    ChongQing, Chongqing 404000, China
  • Novo Nordisk Investigational Site
    Fuzhou, Fujian 350001, China
  • Novo Nordisk Investigational Site
    Guangzhou, Guangdong 510120, China
  • Novo Nordisk Investigational Site
    Guangzhou, Guangdong 510515, China
  • Novo Nordisk Investigational Site
    Hengshui, Hebei 053000, China
  • Novo Nordisk Investigational Site
    Shijiazhuang, Hebei 050000, China
  • Novo Nordisk Investigational Site
    Tangshan, Hebei 063000, China
  • Novo Nordisk Investigational Site
    Harbin, Heilongjiang 150001, China
  • Novo Nordisk Investigational Site
    Yueyang, Hunan 414000, China
  • Novo Nordisk Investigational Site
    Huhehaote, Inner Mongolia 010020, China
  • Novo Nordisk Investigational Site
    Huhhot, Inner Mongolia 010050, China
  • Novo Nordisk Investigational Site
    Changzhou, Jiangsu 213003, China
  • Novo Nordisk Investigational Site
    Nanjing, Jiangsu 210011, China
  • Novo Nordisk Investigational Site
    Nanjing, Jiangsu 210012, China
  • Novo Nordisk Investigational Site
    Nanjing, Jiangsu 210029, China
  • Novo Nordisk Investigational Site
    Zhenjiang, Jiangsu 212001, China
  • Novo Nordisk Investigational Site
    Nanchang, Jiangxi 330006, China
  • Novo Nordisk Investigational Site
    Changchun, Jilin 130021, China
  • Novo Nordisk Investigational Site
    Changchun, Jilin 130033, China
  • Novo Nordisk Investigational Site
    Siping, Jilin 136000, China
  • Novo Nordisk Investigational Site
    Dalian, Liaoning 116011, China
  • Novo Nordisk Investigational Site
    Yinchuan, Ningxia 750004, China
  • Novo Nordisk Investigational Site
    Xi'an, Shaanxi 710061, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200040, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200072, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200240, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 201199, China
  • Novo Nordisk Investigational Site
    Taiyuan, Shanxi 030001, China
  • Novo Nordisk Investigational Site
    Tianjin, Tianjin 300052, China
  • Novo Nordisk Investigational Site
    Kunming, Yunnan 650101, China
  • Novo Nordisk Investigational Site
    Shatin, New Territories, Hong Kong
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Mar 2019, 21 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
Jun 5, 2017
StartActual
May 26, 2017
Primary completionActual
Mar 5, 2019
CompletionActual
Apr 4, 2019
Results first posted
Mar 19, 2020
Last update
Mar 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03175120
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
May 26, 2017
Primary completion
Mar 5, 2019
Completion
Apr 4, 2019
Results posted
Mar 19, 2020
Last update
Mar 19, 2020

Study contacts

Global Clinical Registry (GCR,1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion